Health Care • Medical Specialities
$36.14 ▲ +0.69
(+1.95%)
MKT CAP: $10.21B • VOL: 3.79M
52W L $14 52W H $37
CAI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $812.0M | $412.3M | $306.1M |
| YoY Revenue Growth % | +97.0% | +34.7% | — |
| Gross Profit | $357.3M | $181.4M | $134.7M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $45.1M | -$257.1M | -$319.6M |
| Operating Margin % | 5.6% | -62.4% | -104.4% |
| Net Income (GAAP) | -$68.1M | -$281.9M | -$341.4M |
| EBITDA (Normalized) | $58.1M | -$250.4M | -$308.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $83.2M | -$245.2M | -$276.1M |
| Capital Expenditures (CapEx) | $16.3M | $8.4M | $13.8M |
| Free Cash Flow (FCF) | $66.9M | -$253.6M | -$289.9M |
| FCF Margin % | 8.2% | -61.5% | -94.7% |
| Return on Invested Capital (ROIC %) | 22.3% | -45.0% | -7.4% |
| Cash & Short-Term Equivalents | $796.3M | $64.0M | $617.9M |
| Total Debt (Short + Long Term) | $378.8M | $319.4M | $1.31B |
| Total Stockholders' Equity | $577.3M | -$2.50B | $2.70B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CAI.